Financial Performance - The company's operating revenue for Q1 2022 was ¥930,726,704.79, representing a year-on-year increase of 37.38%[5] - Net profit attributable to shareholders was ¥183,697,243.65, reflecting a growth of 15.28% compared to the same period last year[5] - Total operating revenue for Q1 2022 reached ¥930.73 million, a 37.4% increase from ¥677.47 million in Q1 2021[48] - Net profit for Q1 2022 was ¥193.60 million, representing a 19.4% increase compared to ¥162.12 million in Q1 2021[48] - Earnings per share for Q1 2022 were ¥0.29, compared to ¥0.25 in Q1 2021[50] - Cash received from sales of goods and services in Q1 2022 was ¥732.57 million, an increase from ¥549.86 million in Q1 2021[50] Cash Flow - The net cash flow from operating activities was -¥19,559,417.10, a decrease of 130.85% year-on-year[5] - The net cash flow from operating activities decreased to -$19.56 million from $63.40 million year-over-year, indicating a significant decline in operational performance[54] - Cash received from operating activities totaled $751.78 million, an increase from $566.33 million, suggesting improved revenue generation[54] - Cash inflow from investment activities totaled $864.38 million, down from $1,076.48 million, reflecting a decrease in investment recovery[54] - Cash outflow for investment activities was $679.97 million, compared to $1,130.51 million in the previous period, showing a reduction in capital expenditures[54] - The net cash flow from financing activities was -$299,643.48, indicating that the company had a net outflow in this category[56] - The ending cash and cash equivalents balance was $353.16 million, down from $867.00 million, highlighting a significant decrease in liquidity[56] Assets and Liabilities - Total assets at the end of Q1 2022 amounted to ¥6,093,177,254.01, an increase of 1.59% from the end of the previous year[7] - The total assets of the company reached approximately ¥6,093,177,254.01 as of March 31, 2022, compared to ¥5,997,600,248.38 at the end of December 2021, reflecting an increase of about 1.6%[42] - The total current assets increased to ¥4,154,053,584.91 from ¥4,064,479,153.32, representing a rise of about 2.2% year-over-year[39] - The total liabilities included accounts payable of ¥258,589,397.24, which increased from ¥163,094,814.55, marking a significant rise of about 58.6%[42] - The total liabilities decreased to ¥1,317.09 million in Q1 2022 from ¥1,415.11 million in Q1 2021[44] - The total equity increased to ¥4,776.08 million in Q1 2022 from ¥4,582.49 million in Q1 2021[44] Shareholder Information - Total number of ordinary shareholders at the end of the reporting period is 47,555[16] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[16] - The second largest shareholder, Central Huijin Asset Management Co., Ltd., holds 15,551,120 shares, representing 2.47% of total shares[16] - The company repurchased 566,042 shares, reducing the total outstanding shares to 629,433,958[7] - The company has no pledged, marked, or frozen shares among the top ten shareholders[16] - The company has no related party or concerted action relationships with the top ten shareholders[19] Investment and Financial Products - The company has a total of 675,000 RMB in overdue principal from entrusted loans, with legal proceedings initiated to recover the amount[21] - The company has completed the granting of 510,000 restricted stocks under the 2021 stock incentive plan to 17 incentive objects[22] - The company has entrusted a total of 50 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.32%[25] - The company has also entrusted another 100 million RMB in non-principal guaranteed floating income financial products with an annualized return rate of 4.45%[25] - The company has a total of 100 million RMB in entrusted financial products maturing on June 6, 2022, with a return rate of 3.95%[25] - The company reported a total of ¥2,256,017,632.60 in fixed income products, with a weighted average interest rate of 3.55%[36] - The company has plans for market expansion and new product development, focusing on fixed income products to enhance revenue streams[36] Expenses - Total operating costs for Q1 2022 were ¥721.70 million, up 42.8% from ¥505.25 million in Q1 2021[48] - Research and development expenses for Q1 2022 totaled ¥27.97 million, a 44.7% increase from ¥19.36 million in Q1 2021[48] - Sales expenses in Q1 2022 were ¥353.21 million, up 60.5% from ¥219.75 million in Q1 2021[48] - Cash paid for employee compensation increased to $191.33 million from $146.47 million, reflecting higher personnel costs[54] - Cash paid for taxes rose to $74.98 million from $67.63 million, indicating an increase in tax obligations[54] Investment Income - The company reported a significant increase in investment income, reaching ¥1.19 million in Q1 2022 compared to a loss of ¥0.09 million in Q1 2021[48] - Cash received from investment income was $9.34 million, down from $13.43 million, showing a decline in investment returns[54] - Cash inflow from the recovery of investments was $855.02 million, down from $1,063.00 million, indicating a decrease in cash recovery from investments[54]

Financial Performance - The company's operating revenue for 2021 was CNY 2,873,974,462.18, representing a 17.72% increase compared to CNY 2,441,451,789.23 in 2020[29]. - The net profit attributable to shareholders for 2021 was CNY 505,687,248.49, a 6.74% increase from CNY 473,739,388.42 in 2020[29]. - The net cash flow from operating activities for 2021 was CNY 917,037,660.75, up 21.87% from CNY 752,501,253.68 in 2020[29]. - The total assets at the end of 2021 were CNY 5,997,600,248.38, reflecting a 21.81% increase from CNY 4,923,573,835.05 at the end of 2020[29]. - The basic earnings per share for 2021 was CNY 0.80, a 6.67% increase from CNY 0.75 in 2020[29]. - The company reported a decrease of 4.58% in net profit attributable to shareholders after deducting non-recurring gains and losses, totaling CNY 424,156,470.17 in 2021 compared to CNY 444,526,688.21 in 2020[29]. - The total cash dividend for 2021, including the share buyback amounting to CNY 73.27 million, is CNY 621.01 million, representing 122.80% of the net profit attributable to the parent company[7]. Business Segments and Growth - The OTC (over-the-counter) business generated an annual revenue of 2.158 billion yuan, reflecting a year-on-year increase of 14.11%[42]. - The prescription drug business reported an annual revenue of 453 million yuan, with a growth of 27.04% due to the inclusion of Hais Pharmaceutical's business[43]. - The health products segment achieved an annual revenue of 245 million yuan, marking a year-on-year growth of 31.24%[44]. - The company acquired a 51% stake in Hais Pharmaceutical for approximately 220 million yuan, enhancing its product offerings in the gastrointestinal sector[45]. - The company launched a new joint development project for probiotics aimed at treating IBS and IBD, indicating a focus on innovative drug development[46]. Research and Development - Research and development expenses increased by 58.09% to 87.82 million RMB, indicating a significant investment in innovation[65]. - The company invested a total of 1,318.76 million RMB in the development and evaluation of probiotic products, representing 0.46% of operating revenue, with a year-on-year increase of 181.54%[128]. - The development of traditional Chinese medicine classic formulas incurred R&D expenses of 760.25 million RMB, which is 0.26% of operating revenue, showing a significant increase of 147.36% year-on-year[128]. - The company is developing a new probiotic drug for treating IBS and IBD, currently in the pre-research stage[128]. Market and Industry Trends - The overall growth rate of the pharmaceutical industry is slowing down, with increased market consolidation and elimination of less competitive companies[105]. - The non-prescription drug (OTC) market is expected to grow significantly, driven by an aging population and increased self-medication practices, with 29 prescription drugs converted to OTC in 2021[104]. - The "Internet + Healthcare" sector is poised for rapid development, with clearer regulations and increased policy support following the COVID-19 pandemic[104]. - The healthcare industry is transitioning from high-speed growth to high-quality development, presenting both challenges and opportunities[105]. Corporate Governance and Management - The company adheres to strict corporate governance practices, ensuring compliance with relevant laws and regulations[159]. - The company has made commitments to maintain operational independence from its controlling shareholders, addressing potential conflicts of interest[162]. - The company held a total of 4 shareholder meetings during the reporting period, all of which complied with legal and regulatory requirements[165]. - The company has appointed new independent directors and supervisors to enhance governance and oversight[168]. - The company’s board of directors is actively involved in overseeing the implementation of the incentive plan and related management practices[168]. Strategic Initiatives - The company plans to achieve the goal of "recreating Jiangzhong" by the end of the 14th Five-Year Plan through internal growth and external acquisitions[39]. - The company aims to enhance brand recognition and consumer acceptance to counteract the risks associated with procurement policies[110]. - The company is focusing on financial investments and strategic acquisitions to drive future growth[167]. - The company plans to continue expanding its market presence and developing new products as part of its growth strategy[171].

Financial Performance - The company's operating revenue for Q3 2021 was ¥671,621,213.03, representing a year-on-year increase of 16.46%[7] - The net profit attributable to shareholders for Q3 2021 was ¥145,264,068.66, with a year-on-year growth of 13.45%[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥125,433,613.19, reflecting an 8.86% increase compared to the same period last year[7] - Total operating revenue reached ¥1,937,836,872.68, an increase from ¥1,735,158,093.44, representing a growth of approximately 11.7% year-over-year[57] - Net profit for the period was ¥466,437,225.31, compared to ¥410,799,666.67, indicating a growth of approximately 13.5% year-over-year[61] - Basic earnings per share increased to ¥0.72 from ¥0.63, marking a rise of about 14.3% year-over-year[63] - The company reported a profit before tax of ¥556,267,148.77, up from ¥487,477,675.55, representing an increase of about 14.1% year-over-year[61] - The total comprehensive income for the period was ¥466,437,225.31, compared to ¥410,799,666.67, indicating a growth of approximately 13.5% year-over-year[63] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥5,147,517,955.61, an increase of 4.55% from the end of the previous year[10] - The total current assets increased to CNY 3,490,168,938.52 compared to CNY 3,275,216,063.89 at the end of 2020, reflecting a growth of approximately 6.55%[48] - The total liabilities amounted to CNY 679,075,934.40, slightly up from CNY 672,273,995.31 in the previous year[53] - The company's equity attributable to shareholders increased to CNY 4,085,332,676.23 from CNY 3,876,867,968.11, representing a growth of about 5.39%[53] - The total non-current assets slightly increased to CNY 1,657,349,017.09 from CNY 1,648,357,771.16 year-over-year[51] Shareholder Information - The total number of common shareholders at the end of the reporting period is 48,370[19] - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, accounting for 43.03% of total shares[19] - The company repurchased a total of 6,300,042 shares, representing 1.00% of the total share capital, with an average repurchase price of 11.63 RMB per share[23] - The highest price during the share repurchase was 11.88 RMB per share, and the lowest was 11.34 RMB per share[23] Wealth Management and Investments - The company has entrusted a total of 300 million RMB in wealth management with a floating income type, achieving an annualized return rate of 3.35%[31] - Another wealth management amounting to 100 million RMB was entrusted, also with a floating income type, yielding an annualized return of 3.50%[31] - A total of 150 million RMB was invested in a floating income wealth management product, with an actual return of 5,134,931.51 RMB, reflecting a 3.50% annualized return[31] - The company has diversified its investments across multiple banks, ensuring a balanced portfolio with varying return rates[35] - The total expected return from various wealth management products is projected to be substantial, with actual returns being closely monitored[31] - The company continues to explore new wealth management opportunities to enhance its financial performance[31] Legal and Compliance - The company’s legal department has filed a lawsuit to recover overdue loan amounts from Changrong Automobile[28] - The company has received approval from the State-owned Assets Supervision and Administration Commission for the implementation of the restricted stock incentive plan[24] - The company has implemented new leasing standards starting from 2021, affecting the financial statements[68] - The company confirmed the recognition of right-of-use assets and related lease liabilities under the new leasing standard[73] Research and Development - Research and development expenses rose to ¥47,762,731.83 from ¥33,740,433.65, showing an increase of approximately 41.5% year-over-year[57]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[17]. - Net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[17]. - The company’s gross margin improved to 45%, an increase of 5 percentage points year-on-year[17]. - The management has provided a revenue guidance of RMB 2.5 billion for the full year 2021, indicating a growth target of 12%[17]. - The company's operating revenue for the first half of the year reached ¥1,266,215,659.65, representing a 9.30% increase compared to the same period last year[23]. - Net profit attributable to shareholders was ¥306,567,048.05, reflecting a growth of 13.54% year-on-year[23]. - The basic earnings per share increased to ¥0.49, a rise of 13.95% compared to the previous year[23]. - The company achieved a net profit attributable to the parent company of 307 million yuan, an increase of 37 million yuan, representing a growth of 13.54% year-on-year[41]. - The company's total operating revenue reached 1.266 billion yuan, an increase of 108 million yuan, with a year-on-year growth of 9.30%[47]. - The company reported a total profit of RMB 371,284,194.32 for the first half of 2021, compared to RMB 332,783,306.18 in the same period of 2020, marking an increase of 11.5%[170]. Research and Development - Research and development expenses increased by 25% to RMB 150 million, reflecting the company's commitment to innovation[17]. - Research and development expenses rose significantly by 43.78% to approximately ¥32.79 million, compared to ¥22.81 million in the previous year[51]. - Research and development expenses increased to RMB 32,793,628.09, a rise of 43.8% from RMB 22,808,057.76 in the previous year[168]. Market Expansion and Product Development - User data indicates a growth in active users by 10% to 2 million during the reporting period[17]. - The company plans to launch three new products in the second half of 2021, focusing on herbal medicine and health supplements[17]. - New products launched in 2021 include Jiangzhong Yitong probiotics and Jiangzhong Yitong Bajin cake, expanding the product line[36]. - The company is focusing on the development of gastrointestinal and chronic disease products, including classic formulas and new Chinese medicines[47]. - The company continues to focus on the production and sales of over-the-counter drugs, prescription drugs, and health products, with no major changes in its main business[34]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥5,130,122,611.08, up 4.20% from the end of the previous year[23]. - The company's trading financial assets increased to ¥1,275,824,437.84, accounting for 24.87% of total assets, a 30.07% increase compared to the previous year[58]. - Accounts receivable notes rose significantly to ¥750,008,082.75, representing 14.62% of total assets, with a dramatic increase of 22,500.95% from the previous year[58]. - The company reported a total current assets of 3,484,116,530.22 RMB as of June 30, 2021, compared to 3,275,216,063.89 RMB at the end of 2020, indicating an increase[156]. - Total assets increased to ¥5,130,122,611.08, up from ¥4,923,573,835.05, representing a growth of approximately 4.22% year-over-year[161]. Cash Flow and Investment - The net cash flow from operating activities decreased significantly by 57.22%, amounting to ¥295,406,648.57[23]. - Cash flow from operating activities was CNY 295,406,648.57, down from CNY 690,545,105.25 in the first half of 2020, reflecting a decrease of approximately 57.3%[184]. - The net cash flow from investment activities was CNY -726,654,479.17, an improvement from CNY -970,899,071.37 in the first half of 2020[184]. - Cash inflow from investment activities increased significantly to CNY 1,590,774,528.64, up 196.5% from CNY 535,041,530.98 in the first half of 2020[188]. Environmental and Social Responsibility - The company has received the "Advanced Collective in Ecological Civilization Construction" honor from Jiangxi Provincial Government[97]. - The company has established comprehensive wastewater treatment facilities at both Jiangzhong Medicine Valley and Luoting bases[97]. - The company has implemented a gas boiler system using clean natural gas, achieving SO2 emissions close to zero and meeting the emission standards for nitrogen oxides[114]. - The company has successfully lifted all 49 residents of Nanzhou Village out of poverty through targeted assistance, improving public infrastructure and living conditions[123]. - The company has constructed 4.3 kilometers of new village roads and completed safety drinking water projects for 245 households in Nanzhou Village[125]. Corporate Governance and Shareholder Information - The company approved a restricted stock incentive plan on June 17, 2021, involving 6.3 million shares, accounting for 1.0% of the total share capital[93]. - The total number of common shareholders as of the end of the reporting period is 44,762[146]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group Co., Ltd., holds 271,071,486 shares, representing 43.03% of total shares[146]. - The company has committed to minimizing and regulating related party transactions with Jiangzhong Pharmaceutical, ensuring fair pricing and timely information disclosure[135]. - There are no significant lawsuits or arbitration matters during the reporting period[138].

证券代码：600750 证券简称：江中药业 公告编号：2021-019 江中药业股份有限公司 关于参加江西辖区上市公司 2021 年 投资者集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融 资计划、股权激励、可持续发展等投资者所关心的问题，江中药业股份有限公 司（以下简称"公司"）定于 2021 年 5 月 14 日下午 15:00—17:00 参加由江西 省上市公司协会联合深圳市全景网络有限公司举办的主题为"心系投资者 携手 高质量发展"江西上市公司 2021 年投资者集体接待日活动。现将有关事项公告 如下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net 进 入专区页面参与交流。 出席本次集体接待日的人员有：公司总经理蔡新平先生、财务总监李小俊 先生、董事会秘书田永静女士。 欢迎广大投资者积极参与。 特此公告。 江中药业股份有限公司董事会 2021 年 5 月 11 日 ...

2021 年第一季度报告 公司代码：600750 公司简称：江中药业 江中药业股份有限公司 2021 年第一季度报告 1 / 32 2021 年第一季度报告 | --- | --- | --- | |-------|-------|------------------| | | | | | | | | | | | 目录 | | | | | | | | 一、重要提示 . | | | | 二、公司基本情况 | | | | 三、重要事项 . | | | | 四、附录 . | 2 / 32 2021 年第一季度报告 单位：元 币种：人民币 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人卢小青、主管会计工作负责人李小俊及会计机构负责人（会计主管人员）周违莉 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 | --- | --- | --- | --- | ...

Financial Performance - The company's operating revenue for 2020 was ¥2,441,451,789.23, a decrease of 0.32% compared to 2019[28]. - Net profit attributable to shareholders for 2020 was ¥473,739,388.42, an increase of 2.19% year-over-year[28]. - The net cash flow from operating activities increased by 17.36% to ¥752,501,253.68 in 2020[28]. - The total assets at the end of 2020 were ¥4,923,573,835.05, reflecting a growth of 3.45% from the previous year[28]. - Basic earnings per share for 2020 were ¥0.75, up 1.35% from ¥0.74 in 2019[28]. - The weighted average return on equity decreased by 0.89 percentage points to 12.74% in 2020[28]. - The company achieved a net profit attributable to the parent company of 474 million yuan, an increase of 10 million yuan, representing a growth of 2.19% compared to the same period last year[43]. - The company reported a net profit of ¥131,424,924.09 in Q1 2020, with a total revenue of ¥525,279,630.39 for the same quarter[30]. Dividend Distribution - The proposed cash dividend distribution is 2.7 RMB per 10 shares, totaling 170.1 million RMB, which accounts for 35.91% of the net profit attributable to shareholders[6]. - In 2020, the company distributed cash dividends of RMB 170.1 million, which is 35.91% of the net profit attributable to shareholders of RMB 473.74 million[163]. - In 2019, the cash dividends amounted to RMB 157.5 million, representing 33.97% of the net profit of RMB 463.60 million[163]. - In 2018, the cash dividends were RMB 147 million, which is 31.26% of the net profit of RMB 470.25 million[163]. - The company has adhered to the cash dividend policy as per regulatory guidelines and has maintained a stable cash dividend plan[163]. - The company did not propose a cash profit distribution plan for the reporting period despite having positive distributable profits[166]. Audit and Compliance - The company has received a standard unqualified audit report from Ernst & Young Huaming[5]. - The board of directors and supervisory board members have all attended the board meeting[5]. - The company has appointed Ernst & Young Huaming as its domestic accounting firm[27]. - The company reported no major litigation or arbitration matters during the reporting period, reflecting a stable legal standing[180]. - The company has not faced any risks of suspension or termination of its listing, indicating compliance with regulatory requirements[180]. - The company has not made any changes to its accounting policies or estimates during the reporting period, ensuring consistency in financial reporting[179]. Market and Industry Trends - The pharmaceutical industry in China generated revenue of 2,485.73 billion yuan in 2020, with a year-on-year growth of 4.5%[44]. - The pharmaceutical industry is facing challenges such as price reductions and increased market concentration, necessitating strategic adaptations[44]. - The pharmaceutical industry is experiencing a slowdown in overall growth, with increased market concentration and intensified competition due to price reductions and policy reforms[96]. - The demand for the pharmaceutical industry is expected to continue growing due to an aging population and increasing healthcare expenditures, which have risen from 4.9% of GDP in 2003 to 6.6% in 2019[96]. Product Development and Innovation - The company launched new health products in 2020, including probiotics and disinfectant wipes[39]. - The company emphasizes the integration of traditional Chinese medicine theory with modern scientific research to drive product innovation[51]. - The company is focusing on transitioning from a "small and beautiful" model to a "large and strong" development strategy in its 14th Five-Year Plan[59]. - The company is actively developing special medical purpose foods and conducting related research[123]. - The company focused on the development of traditional Chinese medicine products, including classic prescriptions and health products such as probiotics and functional peptides[127]. - The company is committed to developing innovative health products and accelerating the integration of online and offline channels, targeting the "Z generation" for marketing[155]. Strategic Initiatives - The company is expanding its e-commerce sales channels, currently focusing on platforms like Tmall, JD.com, and Pinduoduo[50]. - The company plans to enhance its non-prescription drug business by expanding its gastrointestinal product line and launching new children's products[151]. - The company intends to solidify its existing prescription drug market while covering previously weak markets, focusing on academic promotion and clinical product revitalization[154]. - The company aims to adapt to policy directions to promote the development of new traditional Chinese medicine products[109]. - The company is preparing for the potential impacts of volume-based procurement on traditional Chinese medicine products[108]. Research and Development - Research and development expenses increased by 16.93% to 55.55 million RMB compared to the previous year[64]. - R&D investment represented 2.38% of total revenue, with 246 R&D personnel making up 6.47% of the workforce[87]. - The company invested 375.26 million RMB in the efficacy study of earthworm enzyme, showing a significant increase of 1,822.07% compared to the previous year[131]. - The R&D investment for the classic Chinese medicine product development was 307.35 million RMB, reflecting a 150.50% increase year-on-year[131]. Social Responsibility and Community Engagement - The company invested a total of 820,000 RMB in poverty alleviation efforts, successfully reducing the poverty incidence from 4.97% to 0% in the supported village[194]. - The company facilitated the introduction of new agricultural businesses, generating over 80,000 RMB in additional income for the village collective economy[196]. - The company organized 12 committee meetings and 12 branch meetings to enhance party organization and responsibility in poverty alleviation efforts[196]. - The company has improved public infrastructure in impoverished areas, addressing issues such as transportation, healthcare, electricity, and drinking water[196]. - Total funding for poverty alleviation amounted to 800,000 RMB, with 49 individuals lifted out of poverty[197]. Risk Management - The company faces risks related to raw material prices and supply, particularly for traditional Chinese medicine materials, and will implement strategies to monitor and control costs[158]. - The company is addressing uncertainties related to the pandemic by accelerating marketing, R&D, and new product launches to mitigate operational risks[161]. - The company recognizes the risk of intensified competition in the OTC market due to the growth of internet healthcare and will strengthen brand building and digital marketing capabilities[157].

Financial Performance - Net profit attributable to shareholders of the listed company was ¥398,040,367.58, reflecting a year-on-year increase of 4.30%[17] - Operating income for the first nine months was ¥1,735,158,093.44, up 1.85% from the same period last year[17] - The net cash flow from operating activities for the first nine months was ¥714,502,701.39, an increase of 11.35% year-on-year[17] - Total operating revenue for Q3 2020 was CNY 576,696,483, an increase from CNY 562,694,201 in Q3 2019, representing a growth of 2.0%[72] - Net profit for Q3 2020 was CNY 131,840,980.81, slightly down from CNY 133,499,477.02 in Q3 2019, a decrease of 1.2%[75] - Total comprehensive income attributable to the parent company for the first three quarters of 2020 was approximately ¥398.04 million, up from ¥381.64 million in the same period of 2019[77] Assets and Liabilities - Total assets at the end of the reporting period reached ¥4,793,102,378.24, an increase of 0.71% compared to the end of the previous year[17] - Current liabilities decreased to ¥543,858,700.26 from ¥748,912,845.10, a reduction of approximately 27.4%[61] - Total liabilities decreased to ¥621,326,102.28 from ¥834,837,147.96, a reduction of approximately 25.6%[63] - Total equity increased to ¥4,171,776,275.96 from ¥3,924,356,609.29, reflecting a growth of about 6.3%[63] Revenue Breakdown - Revenue from over-the-counter drugs was ¥1,356,244,387.59, with a year-on-year increase of 2.52%[23] - Revenue from prescription drugs was ¥253,000,999.78, showing a year-on-year decrease of 9.89%[23] - Revenue from the East China region was ¥514,027,424.91, an increase of 7.16% compared to the previous year[24] Cash Flow and Investments - The company's cash and cash equivalents at the end of the period amounted to 291 million RMB, a decrease of 637 million RMB or 68.65% compared to the end of the previous year, primarily due to the investment in bank principal-protected financial products[27] - The net cash flow from investing activities was -1.188 billion RMB, an increase in outflow of 652 million RMB compared to the same period last year, primarily due to the purchase of bank financial products[29] - The net cash flow from operating activities for Q3 2020 was CNY 715,185,378.15, an increase from CNY 599,368,225.16 in Q3 2019, reflecting a growth of about 19.4%[89] Research and Development - Research and development expenses for Q3 2020 amounted to CNY 10,932,375.89, up from CNY 9,840,382.47 in Q3 2019, indicating an increase of 11.1%[72] - Research and development expenses increased to ¥10.93 million in Q3 2020, up 11.1% from ¥9.84 million in Q3 2019[80] Shareholder Information - The company reported a total of 44,593 shareholders at the end of the reporting period[24] - The company has no related party or concerted action relationships with the top ten shareholders, with the controlling shareholder being China Resources Jiangzhong Pharmaceutical Group[27] Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[75]

Financial Performance - The company's operating revenue for the first half of 2020 was RMB 1,158,461,610.44, representing a 1.54% increase compared to RMB 1,140,918,626.22 in the same period last year[20]. - Net profit attributable to shareholders reached ¥270,002,490.49, an increase of 7.14% compared to the previous year[23]. - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥266,370,628.12, reflecting a 13.41% increase year-on-year[23]. - Basic earnings per share rose to ¥0.43, a 7.50% increase from the previous year[23]. - Diluted earnings per share also increased to ¥0.43, marking a 7.50% rise year-on-year[23]. - Operating cash flow net amount increased by 45.72% to ¥690,545,105.25 compared to the same period last year[23]. - The company's operating revenue for the current period is approximately ¥1.16 billion, an increase of 1.54% compared to ¥1.14 billion in the same period last year[48]. - The net cash flow from operating activities increased by 45.72% to approximately ¥690.55 million, up from ¥473.87 million in the previous year[48]. - The company reported a total revenue from sales of goods and services of ¥1,239,656,703.63, compared to ¥872,377,407.86 in the previous year, marking an increase of approximately 42.1%[176]. Risks and Challenges - There were no significant risks that materially affected the company's production and operations during the reporting period[7]. - The company faces risks from intensified market competition and policy changes affecting the OTC industry[70]. - The company has sufficient inventory to mitigate the impact of raw material price fluctuations observed during the pandemic[70]. - The company faced production and operational risks due to COVID-19, including increased logistics and labor costs, but has adapted by implementing flexible work arrangements and online marketing strategies[73]. - The company has noted a significant contribution of TCM in treating COVID-19, which has led to increased trust and support from the government for the TCM industry[73]. Investments and Capital Expenditures - The company plans to invest ¥566 million in the construction of a modern production base for traditional Chinese medicine, with the project already in the planning and design phase[43]. - The company established Jiangzhong E-commerce with a registered capital of 5 million yuan to seize e-commerce opportunities, fully owned by the company[33]. - The company invested in Jiangzhong Jihai Pharmaceutical with a registered capital of 150 million yuan, holding a 51% indirect stake[33]. Product Development and Market Strategy - The company launched new products including Jiangzhong Lihuo probiotics and Rui Jie disinfecting wipes in May[27]. - The company has not disclosed any new product or technology developments in this report[6]. - The company is focusing on developing new products, including probiotics and disinfectant wipes, to better cater to the domestic market[44]. - The company aims to enhance its product offerings in the gastrointestinal medication sector and strengthen channel cooperation through large-scale public relations and consumer interaction activities[44]. Environmental and Social Responsibility - Jiangzhong Pharmaceutical has not experienced any environmental pollution incidents or received administrative penalties during the reporting period[111]. - The company has committed to sustainable development, adhering to ecological civilization principles and environmental protection[132]. - The company invested CNY 20,000 for visiting and comforting impoverished households during the Spring Festival[102]. - The company helped sell over CNY 200,000 worth of unsold agricultural products during the pandemic[103]. - The company secured CNY 300,000 in special poverty alleviation funds from the Agricultural Development Bank of China[109]. Shareholder Information - The total number of ordinary shares increased from 525,000,000 to 630,000,000, representing a 20% increase due to a cash dividend of 3 RMB per 10 shares and a stock bonus of 2 shares for every 10 shares held[137]. - The total number of shareholders reached 36,706 by the end of the reporting period[138]. - The largest shareholder, China Resources Jiangzhong Pharmaceutical Group, holds 271,071,486 shares, accounting for 43.03% of total shares[140]. Compliance and Governance - The company has confirmed that there are no non-operating fund occupations by controlling shareholders and their related parties[7]. - There are no violations of decision-making procedures for providing guarantees to external parties[7]. - The company has committed to resolving existing competition issues with Jiangzhong Pharmaceutical within five years from February 26, 2019[84]. - The company guarantees to maintain the independence of Jiangzhong Pharmaceutical and not to interfere with its operational decisions[90].

证券代码：600750 证券简称：江中药业 公告编号：2020-019 江中药业股份有限公司 | --- | --- | |----------------------------------------------------------------------|-------| | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 | | | 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 为便于广大投资者更深入全面地了解公司情况、发展战略、经营状况、融 资计划、股权激励、可持续发展等投资者所关心的问题，江中药业股份有限公 司（以下简称"公司"）定于 2020 年 7 月 17 日下午 15:00—17:00 参加由江西 省上市公司协会联合深圳市全景网络有限公司举办的主题为"以高质量沟通，促 高质量发展"江西上市公司 2020 年投资者集体接待日活动。现将有关事项公告 如下： 本次集体接待日网上交流网址：投资者可以登录 http://rs.p5w.net 进 入专区页面参与交流。 出席本次集体接待日的人员有：公司总经理蔡新平先生、财务总监李小俊 ...